- Conditions
- Aortic Stenosis, Disorder of Prosthetic Cardiac Valve, Aortic Valve Insufficiency, Mitral Valve Insufficiency, Hypertrophic Cardiomyopathy, Tricuspid Valve Insufficiency
- Interventions
- Blood Draw
- Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 378 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2020
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–60
of 60
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Bleeding Disorder
- Interventions
- Recombinant von Willebrand Factor
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Von Willebrand Diseases, Postpartum Hemorrhage
- Interventions
- Recombinant Von Willebrand factor, Tranexamic Acid Injection [Cyklokapron]
- Drug
- Lead sponsor
- Nicoletta C Machin
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Factor VIII Deficiency
- Interventions
- efanesoctocog alfa (BIVV001)
- Biological
- Lead sponsor
- Bioverativ, a Sanofi company
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 8
- States / cities
- Los Angeles, California • San Diego, California • Gainesville, Florida + 4 more
- Conditions
- Hemophilia A
- Interventions
- Desmopressin
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 60 Years · Female only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Von Willebrand Disease, Type 1, Heavy Menstrual Bleeding
- Interventions
- Volta System
- Device
- Lead sponsor
- Five Liters, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Hemophilia A
- Interventions
- efanesoctocog alfa (BIVV001)
- Drug
- Lead sponsor
- Bioverativ, a Sanofi company
- Industry
- Eligibility
- Up to 11 Years · Male only
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Gainesville, Florida • Atlanta, Georgia + 7 more
- Conditions
- Von Willebrand Disease
- Interventions
- Patients using Wilate as standard of care
- Other
- Lead sponsor
- Octapharma
- Industry
- Eligibility
- Not listed
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 4
- States / cities
- Torrance, California • Miami, Florida • Salt Lake City, Utah + 1 more
- Conditions
- Von Willebrand Diseases
- Interventions
- Not listed
- Lead sponsor
- American Thrombosis and Hemostasis Network
- Network
- Eligibility
- Not listed
- Enrollment
- 108 participants
- Timeline
- 2019 – 2026
- U.S. locations
- 22
- States / cities
- Orange, California • Aurora, Colorado • Farmington, Connecticut + 19 more
- Conditions
- Thrombotic Thrombocytopenic Purpura, Congenital Thrombotic Thrombocytopenic Purpura, Familial Thrombotic Thrombocytopenic Purpura, Thrombotic Thrombocytopenic Purpura, Congenital, Upshaw-Schulman Syndrome
- Interventions
- Observation
- Other
- Lead sponsor
- Insel Gruppe AG, University Hospital Bern
- Other
- Eligibility
- Not listed
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2030
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Von Willebrand's Disease (VWD)
- Interventions
- efanesoctocog alfa (BIVV001)
- Drug
- Lead sponsor
- Bioverativ, a Sanofi company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Iowa City, Iowa • Pittsburgh, Pennsylvania
- Conditions
- Von Willebrand Disease (VWD)
- Interventions
- Vonicog Alfa, ADVATE
- Biological
- Lead sponsor
- Takeda
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Orlando, Florida • Peoria, Illinois + 9 more